Scientists need a better understanding of the chemistry of radium to be able to target the isotope radium-223 (Ra-223) to cancer cells. Once delivered, Ra-223 can destroy those cells with alpha ...
MUNICH — Details of the ERA 223 clinical trial that led to a restriction in Europe of the use of the radiopharmaceutical radium-223 dichloride (Ra-223; Xofigo, Bayer) have now been presented here at ...
Researchers at the University of Sheffield have received new funding to investigate if radium-223 (Ra-223), currently used to treat bone metastases in prostate cancer, might also help in bone spread ...
Patients with metastatic castration-resistant prostate cancer previously treated with external beam radiation therapy did not increase incidence of blood-related side effects with radium-223 compared ...
Radium-223’s (Ra-223) low levels of alpha particle radiation induce double-strand DNA breaks, which leads to cell apoptosis. Sipuleucel-T (SipT), which is an immunotherapy manufactured from a ...
A phase I study of the safety and pharmacokinetics of DSTP3086S, an anti-STEAP1 antibody-drug conjugate (ADC), in patients (pts) with metastatic castration-resistant prostate cancer (CRPC). This is an ...
Randomized phase II trial of radium-223 (RA) plus enzalutamide (EZ) versus EZ alone in metastatic castration-refractory prostate cancer (mCRPC): Final efficacy and safety results. This is an ASCO ...
A phase 2 trial showed that olaparib plus radium 223 prolonged progression-free survival in a subset of patients with castration-resistant prostate cancer and bone metastases. Radiographic progression ...
New results from an early-access, phase 3b trial of radium-223 dichloride (223 Ra) in men with metastatic castration-resistant prostate cancer (mCRPC) corroborate survival and safety data of the ...
Oslo, Norway, 15 November 2013 - Algeta ASA (OSE: ALGETA) announces today that Bayer has received marketing authorisation from the European Commission for Xofigo ® (radium Ra 223 dichloride) solution ...
The high risk of bone involvement in cases of hormone-refractory prostate cancer has previously been treated with bisphosphonates (which reduce the risk of skeletal events but do not extend survival) ...
MUNICH -- Men with bone-predominant metastatic castration-resistant prostate cancer (mCRPC) had worse outcomes when radium-223 (Xofigo) was added to abiraterone (Zytiga) and prednisone, according to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback